Published in Cell on December 13, 2012
Identification of genomic alterations in oesophageal squamous cell cancer. Nature (2014) 3.10
KRAS and YAP1 converge to regulate EMT and tumor survival. Cell (2014) 3.06
The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov (2013) 3.03
Hippo pathway effector Yap promotes cardiac regeneration. Proc Natl Acad Sci U S A (2013) 2.76
The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer (2015) 2.74
Tackling the cancer stem cells - what challenges do they pose? Nat Rev Drug Discov (2014) 2.55
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet (2015) 2.46
Cell adhesion. Mechanical strain induces E-cadherin-dependent Yap1 and β-catenin activation to drive cell cycle entry. Science (2015) 2.45
An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell (2013) 2.30
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci Data (2014) 1.76
A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature (2015) 1.56
Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1. Sci Signal (2015) 1.52
Aberrant activation, nuclear localization, and phosphorylation of Yes-associated protein-1 in the embryonic kidney and Wilms tumor. Pediatr Blood Cancer (2013) 1.46
TIAM1 Antagonizes TAZ/YAP Both in the Destruction Complex in the Cytoplasm and in the Nucleus to Inhibit Invasion of Intestinal Epithelial Cells. Cancer Cell (2017) 1.41
Nerve Growth Factor Promotes Gastric Tumorigenesis through Aberrant Cholinergic Signaling. Cancer Cell (2016) 1.40
Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. Nat Cell Biol (2015) 1.39
Disease implications of the Hippo/YAP pathway. Trends Mol Med (2015) 1.32
TRIB2 acts downstream of Wnt/TCF in liver cancer cells to regulate YAP and C/EBPα function. Mol Cell (2013) 1.29
The Hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment. Cell Rep (2014) 1.24
The role of LPA and YAP signaling in long-term migration of human ovarian cancer cells. Cell Commun Signal (2013) 1.20
Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties. Cancer Res (2014) 1.18
Signal integration in TGF-β, WNT, and Hippo pathways. F1000Prime Rep (2013) 1.15
Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase. Nat Commun (2013) 1.12
Molecular link between vitamin D and cancer prevention. Nutrients (2013) 1.10
SOX2 regulates YAP1 to maintain stemness and determine cell fate in the osteo-adipo lineage. Cell Rep (2013) 1.07
Adhesion to fibronectin regulates Hippo signaling via the FAK-Src-PI3K pathway. J Cell Biol (2015) 1.05
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. Mol Syst Biol (2013) 1.03
Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol (2015) 1.03
Genomic insights into WNT/β-catenin signaling. Trends Pharmacol Sci (2013) 1.00
A novel genome-wide in vivo screen for metastatic suppressors in human colon cancer identifies the positive WNT-TCF pathway modulators TMED3 and SOX12. EMBO Mol Med (2014) 0.99
Heterozygous loss-of-function mutations in YAP1 cause both isolated and syndromic optic fissure closure defects. Am J Hum Genet (2014) 0.98
β-Catenin destruction complex-independent regulation of Hippo-YAP signaling by APC in intestinal tumorigenesis. Genes Dev (2015) 0.96
Wnt signaling in cancer. Oncogene (2016) 0.95
Emerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancer. J Hepatol (2015) 0.95
α-Catenin interacts with APC to regulate β-catenin proteolysis and transcriptional repression of Wnt target genes. Genes Dev (2013) 0.93
c-Abl antagonizes the YAP oncogenic function. Cell Death Differ (2014) 0.92
The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells. Mol Cell Biol (2015) 0.91
Transcriptional regulation of effector and memory CD8+ T cell fates. Curr Opin Immunol (2013) 0.91
Integration of mechanical and chemical signals by YAP and TAZ transcription coactivators. Cell Biosci (2013) 0.91
The evolving roles of canonical WNT signaling in stem cells and tumorigenesis: implications in targeted cancer therapies. Lab Invest (2015) 0.91
Protein kinase PKN1 represses Wnt/β-catenin signaling in human melanoma cells. J Biol Chem (2013) 0.91
The hippo pathway in heart development, regeneration, and diseases. Circ Res (2015) 0.91
Functional screening identifies miRNAs influencing apoptosis and proliferation in colorectal cancer. PLoS One (2014) 0.90
Nuclear signaling from cadherin adhesion complexes. Curr Top Dev Biol (2015) 0.90
Repression of Intestinal Stem Cell Function and Tumorigenesis through Direct Phosphorylation of β-Catenin and Yap by PKCζ Cell Rep (2015) 0.90
The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression. EMBO Mol Med (2015) 0.90
Impact of the physical microenvironment on tumor progression and metastasis. Curr Opin Biotechnol (2016) 0.89
A miR-130a-YAP positive feedback loop promotes organ size and tumorigenesis. Cell Res (2015) 0.89
Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leukemia (2014) 0.88
A Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue Sarcomas. Front Oncol (2015) 0.88
Control of Proliferation and Cancer Growth by the Hippo Signaling Pathway. Mol Cancer Res (2015) 0.87
The Hippo pathway in disease and therapy: cancer and beyond. Clin Transl Med (2014) 0.87
Increased TEAD4 expression and nuclear localization in colorectal cancer promote epithelial-mesenchymal transition and metastasis in a YAP-independent manner. Oncogene (2015) 0.86
Mst1 and Mst2 kinases: regulations and diseases. Cell Biosci (2013) 0.85
SOX9 drives WNT pathway activation in prostate cancer. J Clin Invest (2016) 0.85
Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma. Oncotarget (2015) 0.84
The Regulatory Machinery of Neurodegeneration in In Vitro Models of Amyotrophic Lateral Sclerosis. Cell Rep (2015) 0.84
Yap reprograms glutamine metabolism to increase nucleotide biosynthesis and enable liver growth. Nat Cell Biol (2016) 0.83
Implications of epithelial-mesenchymal plasticity for heterogeneity in colorectal cancer. Front Oncol (2015) 0.83
Tissue- and stage-specific Wnt target gene expression is controlled subsequent to β-catenin recruitment to cis-regulatory modules. Development (2016) 0.83
Cadherin signaling: keeping cells in touch. F1000Res (2015) 0.83
FOXP1 potentiates Wnt/β-catenin signaling in diffuse large B cell lymphoma. Sci Signal (2015) 0.83
Cis-regulatory architecture of a brain signaling center predates the origin of chordates. Nat Genet (2016) 0.83
FGF8 promotes colorectal cancer growth and metastasis by activating YAP1. Oncotarget (2015) 0.83
The Hippo pathway in intestinal regeneration and disease. Nat Rev Gastroenterol Hepatol (2016) 0.82
Organ size control is dominant over Rb family inactivation to restrict proliferation in vivo. Cell Rep (2014) 0.82
Alternate RASSF1 Transcripts Control SRC Activity, E-Cadherin Contacts, and YAP-Mediated Invasion. Curr Biol (2015) 0.82
Genomic analysis and selective small molecule inhibition identifies BCL-X(L) as a critical survival factor in a subset of colorectal cancer. Mol Cancer (2015) 0.82
Correlations between TBL1XR1 and recurrence of colorectal cancer. Sci Rep (2017) 0.81
Polyomavirus small T antigen interacts with yes-associated protein to regulate cell survival and differentiation. J Virol (2014) 0.81
αE-catenin inhibits a Src-YAP1 oncogenic module that couples tyrosine kinases and the effector of Hippo signaling pathway. Genes Dev (2016) 0.81
Nicotine activates YAP1 through nAChRs mediated signaling in esophageal squamous cell cancer (ESCC). PLoS One (2014) 0.81
Wnt activated β-catenin and YAP proteins enhance the expression of non-coding RNA component of RNase MRP in colon cancer cells. Oncotarget (2015) 0.81
Tyrosine phosphorylation of WW proteins. Exp Biol Med (Maywood) (2015) 0.80
Verteporfin inhibits YAP function through up-regulating 14-3-3σ sequestering YAP in the cytoplasm. Am J Cancer Res (2015) 0.80
PML Surfs into HIPPO Tumor Suppressor Pathway. Front Oncol (2013) 0.80
The cellular prion protein PrPc is a partner of the Wnt pathway in intestinal epithelial cells. Mol Biol Cell (2015) 0.79
Addiction to multiple oncogenes can be exploited to prevent the emergence of therapeutic resistance. Proc Natl Acad Sci U S A (2014) 0.79
Emerging role of Hippo pathway in gastric and other gastrointestinal cancers. World J Gastroenterol (2016) 0.79
The Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma. J Pathol (2016) 0.79
The Hippo signaling pathway provides novel anti-cancer drug targets. Oncotarget (2016) 0.79
Activating CAR and β-catenin induces uncontrolled liver growth and tumorigenesis. Nat Commun (2015) 0.78
YAP1 enhances cell proliferation, migration, and invasion of gastric cancer in vitro and in vivo. Oncotarget (2016) 0.78
LATS2-mediated YAP1 phosphorylation is involved in HCC tumorigenesis. Int J Clin Exp Pathol (2015) 0.78
New insights into posttranslational modifications of Hippo pathway in carcinogenesis and therapeutics. Cell Div (2016) 0.78
Tumorigenesis: WNT branches out. Nat Rev Cancer (2013) 0.78
MicroRNA profiling of cisplatin-resistant oral squamous cell carcinoma cell lines enriched with cancer-stem-cell-like and epithelial-mesenchymal transition-type features. Sci Rep (2016) 0.78
Prognostic Value of Yes-Associated Protein 1 (YAP1) in Various Cancers: A Meta-Analysis. PLoS One (2015) 0.78
Mouse models of colorectal cancer as preclinical models. Bioessays (2015) 0.78
The 1918 Influenza Virus PB2 Protein Enhances Virulence through the Disruption of Inflammatory and Wnt-Mediated Signaling in Mice. J Virol (2015) 0.78
Wnt versus Hippo: A balanced act or dynamic duo? Genes Dis (2014) 0.77
Characterizing genomic alterations in cancer by complementary functional associations. Nat Biotechnol (2016) 0.77
MUC1-C Represses the Crumbs Complex Polarity Factor CRB3 and Downregulates the Hippo Pathway. Mol Cancer Res (2016) 0.77
A novel phosphatidic acid-protein-tyrosine phosphatase D2 axis is essential for ERBB2 signaling in mammary epithelial cells. J Biol Chem (2015) 0.77
N-cadherin functions as a growth suppressor in a model of K-ras-induced PanIN. Oncogene (2015) 0.76
Genetic and Proteomic Interrogation of Lower Confidence Candidate Genes Reveals Signaling Networks in β-Catenin-Active Cancers. Cell Syst (2016) 0.76
Fat4 suppression induces Yap translocation accounting for the promoted proliferation and migration of gastric cancer cells. Cancer Biol Ther (2016) 0.76
The T-box transcription factor 3 is a promising biomarker and a key regulator of the oncogenic phenotype of a diverse range of sarcoma subtypes. Oncogenesis (2016) 0.76
Hippo activation in arrhythmogenic cardiomyopathy. Circ Res (2014) 0.76
A preclinical evaluation of antimycin a as a potential antilung cancer stem cell agent. Evid Based Complement Alternat Med (2013) 0.76
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Comprehensive molecular characterization of human colon and rectal cancer. Nature (2012) 34.13
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Wnt/beta-catenin signaling in development and disease. Cell (2006) 30.09
Lessons from hereditary colorectal cancer. Cell (1996) 25.73
Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science (1997) 24.61
Identification of c-MYC as a target of the APC pathway. Science (1998) 24.25
Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science (1997) 22.80
Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev (2007) 13.05
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell (2006) 12.72
Role of YAP/TAZ in mechanotransduction. Nature (2011) 11.56
The hippo signaling pathway in development and cancer. Dev Cell (2010) 10.54
TEAD mediates YAP-dependent gene induction and growth control. Genes Dev (2008) 9.88
Wnt signalling and its impact on development and cancer. Nat Rev Cancer (2008) 8.37
YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol (2007) 8.11
Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A (2006) 8.01
Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell (2007) 7.60
Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell (2009) 7.39
Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet (2011) 5.67
A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev (2010) 5.38
Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science (2011) 4.76
The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol (2011) 4.63
Expression of Yes-associated protein in common solid tumors. Hum Pathol (2008) 4.61
The Hippo pathway regulates Wnt/beta-catenin signaling. Dev Cell (2010) 4.49
Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A (2011) 4.15
Sustained in vitro intestinal epithelial culture within a Wnt-dependent stem cell niche. Nat Med (2009) 3.82
Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev (2012) 3.48
Co-occupancy by multiple cardiac transcription factors identifies transcriptional enhancers active in heart. Proc Natl Acad Sci U S A (2011) 3.18
Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol (2007) 3.11
Characterization of a novel protein-binding module--the WW domain. FEBS Lett (1995) 3.11
Rac1 activation controls nuclear localization of beta-catenin during canonical Wnt signaling. Cell (2008) 3.02
A two-step model for colon adenoma initiation and progression caused by APC loss. Cell (2009) 2.80
Elevated expression of axin2 and hnkd mRNA provides evidence that Wnt/beta -catenin signaling is activated in human colon tumors. Proc Natl Acad Sci U S A (2001) 2.77
Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol (2008) 2.75
Dynamics of adherens junctions in epithelial establishment, maintenance, and remodeling. J Cell Biol (2011) 2.67
Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. Proc Natl Acad Sci U S A (2011) 2.54
The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci U S A (2012) 2.51
A WW domain protein TAZ is a critical coactivator for TBX5, a transcription factor implicated in Holt-Oram syndrome. Proc Natl Acad Sci U S A (2005) 2.50
Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage. Mol Cell (2008) 2.38
Lentiviral vectors to probe and manipulate the Wnt signaling pathway. PLoS One (2010) 2.28
Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. EMBO J (2004) 2.12
A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. Proc Natl Acad Sci U S A (2008) 2.10
The T-box genes Tbx4 and Tbx5 regulate limb outgrowth and identity. Nature (1999) 2.01
APC mutant zebrafish uncover a changing temporal requirement for wnt signaling in liver development. Dev Biol (2008) 1.90
Wnt/β-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells. J Biol Chem (2012) 1.89
Herding Hippos: regulating growth in flies and man. Curr Opin Cell Biol (2009) 1.77
Elevated c-yes tyrosine kinase activity in premalignant lesions of the colon. Gastroenterology (1995) 1.66
Regulation of mouse embryonic stem cell self-renewal by a Yes-YAP-TEAD2 signaling pathway downstream of LIF. J Cell Sci (2011) 1.62
Scribble participates in Hippo signaling and is required for normal zebrafish pronephros development. Proc Natl Acad Sci U S A (2009) 1.57
T-cell factor 4 functions as a tumor suppressor whose disruption modulates colon cell proliferation and tumorigenesis. Proc Natl Acad Sci U S A (2011) 1.54
TBX5 mutations and congenital heart disease: Holt-Oram syndrome revealed. Curr Opin Cardiol (2004) 1.52
Epithelial cell proliferation in the developing zebrafish intestine is regulated by the Wnt pathway and microbial signaling via Myd88. Proc Natl Acad Sci U S A (2010) 1.47
The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli. J Biol Chem (2002) 1.44
Embedding, serial sectioning and staining of zebrafish embryos using JB-4 resin. Nat Protoc (2010) 1.26
Expression analyses of zebrafish transferrin, ifabp, and elastaseB mRNAs as differentiation markers for the three major endodermal organs: liver, intestine, and exocrine pancreas. Dev Dyn (2004) 1.22
Role of a BCL9-related beta-catenin-binding protein, B9L, in tumorigenesis induced by aberrant activation of Wnt signaling. Cancer Res (2004) 1.21
β-Catenin 1 and β-catenin 2 play similar and distinct roles in left-right asymmetric development of zebrafish embryos. Development (2012) 1.05
Role of Yes kinase during early zebrafish development. Dev Biol (2005) 1.04
Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells. Int J Cancer (2011) 0.97
yap is required for the development of brain, eyes, and neural crest in zebrafish. Biochem Biophys Res Commun (2009) 0.95
Essential role for Csk upstream of Fyn and Yes in zebrafish gastrulation. Mech Dev (2006) 0.90
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Initial sequencing and comparative analysis of the mouse genome. Nature (2002) 96.15
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet (2003) 53.59
Integrative genomics viewer. Nat Biotechnol (2011) 42.83
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
GenePattern 2.0. Nat Genet (2006) 29.07
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform (2012) 23.58
ARACHNE: a whole-genome shotgun assembler. Genome Res (2002) 22.72
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell (2006) 18.81
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42
Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature (2002) 15.36
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
Whole-genome sequence assembly for mammalian genomes: Arachne 2. Genome Res (2003) 12.30
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature (2011) 11.31
Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87
Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci U S A (2004) 10.47
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol (2011) 9.60
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature (2008) 8.38
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
Molecular signatures database (MSigDB) 3.0. Bioinformatics (2011) 8.08
Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA (2003) 8.07
Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. Science (2007) 8.07
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature (2011) 8.03
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Pan-cancer patterns of somatic copy number alteration. Nat Genet (2013) 7.73
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell (2007) 7.60
Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature (2007) 7.55
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med (2009) 7.17
mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature (2007) 7.12
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet (2011) 6.89
A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med (2006) 6.86
GSEA-P: a desktop application for Gene Set Enrichment Analysis. Bioinformatics (2007) 6.63
A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol (2004) 6.61
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell (2009) 6.55
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 6.39
Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature (2008) 6.24
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Unbiased reconstruction of a mammalian transcriptional network mediating pathogen responses. Science (2009) 6.07
Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest (2003) 6.04
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med (2005) 6.04
Efficient mapping of mendelian traits in dogs through genome-wide association. Nat Genet (2007) 5.99
Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods (2006) 5.96
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
Comment on "The consensus coding sequences of human breast and colorectal cancers". Science (2007) 5.88
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
Augmented Wnt signaling in a mammalian model of accelerated aging. Science (2007) 5.62
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol (2005) 5.56
High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov (2011) 5.30
Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature (2012) 5.23
Scoring diverse cellular morphologies in image-based screens with iterative feedback and machine learning. Proc Natl Acad Sci U S A (2009) 5.15
Transparent adult zebrafish as a tool for in vivo transplantation analysis. Cell Stem Cell (2008) 5.09